Zimmer Biomet announces Q4 and full-year 2023 financial results

Zimmer Biomet Holdings, Inc.  reported financial results for the quarter and year ended December 31, 2023. The Company reported fourth quarter net sales of $1.940 billion, an increase of 6.3% over the prior year period, and an increase of 6.1% on a constant currency1 basis. Net sales for the full year were $7.394 billion, an increase of 6.5% over the prior year, and an increase of 7.5% on a constant currency1 basis. Net earnings for the fourth quarter were $419.2 million, or $458.1 million on an adjusted1 basis. For the full year, net earnings were $1.024 billion, or $1.584 billion on an adjusted1 basis.

Diluted earnings per share were $2.01 for the fourth quarter, and adjusted1 diluted earnings per share were $2.20. Full-year diluted earnings per share were $4.88, and adjusted1 diluted earnings per share were $7.55.

“We are pleased to conclude a very successful year with strong fourth quarter results driven by consistent execution, including a healthy second-half growth profile,” said Ivan Tornos, Zimmer Biomet’s President and Chief Executive Officer. “I’m confident in our ability to carry our 2023 momentum into 2024 and to create further value for our stakeholders. As we look ahead, we remain laser focused on our priorities to advance people and culture, achieve operational excellence and drive innovation and diversification to deliver on our Mission.”

Financial guidance
The Company is providing the following full-year 2024 financial guidance:

MB Bureau